Use of pharmacokinetic data below lower limit of quantitation values

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2628-2631

  Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Analytical methodology; Biomarkers; Limit of quantitation; Pharmacokinetics

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE;

BELOW LOWER LIMIT OF QUANTITATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DISTRIBUTION; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; MASS FRAGMENTOGRAPHY; NOTE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY ANALYSIS;

HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84866733509     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0805-6     Document Type: Note

References (17)

1. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), May 2001.
2. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Workshop/Conference Report -Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. AAPS J. 2007;9:E30-42.
3. Humbert H, Cabiac MD, Barradas J, Gerbeau C. Evaluation of pharmacokinetic studies: Is it useful to take into account concentrations below the limit of quantification? Pharm Res. 1996;13:839-45.
4. Jusko WJ, Pyszczynski NA, Bushway MS, D'Ambrosio R, Mis SM. Fifteen Years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma. J Chrom Biomed Appl. 1994;658:47-54.
5. Parasrampuria DA, de Boer P, Desai-Krieger D, Chow AT, Jones CR. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: A first-in-human study. J Clin Pharmacol. 2003;43:406-13.
6. Kong A-N, Ludwig EA, Slaughter RL, DiStefano PM, DeMasi J, Middleton E, et al. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther. 1989;46:616-28.
7. Qu J, Qu Y, Straubinger RM. Ultra-sensitive quantification of corticosteroids in plasma samples using selective solid-phase extraction and reversed-phase capillary high-performance liquid chromatography/tandem mass spectrometry. Anal Chem. 2007; 79:3786-94.
8. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied Pharmacokinetics & Pharmacodynamics. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 9-29.
9. Holford N, Jelliffe R, et al. Pharm PK Discussion -BLQ Values. http://www.boomer.org/pkin/PK07/PK2007116.html.
10. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokin Pharmacodyn. 2001;28:481-504.
11. Duval V, Karlsson MO. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res. 2002;19:1835-40.
12. Ahn JE, Karlsson MO, Dunn A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401-21.
13. Byon W, Fletcher CV, Brundage RC. Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn. 2008;35:101-16.
14. Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11: 371-80.
15. Nix ABJ, Wilson DW. Assay detection limits: Concept, definition, and estimation. Eur J Clin Pharmacol. 1990;39:203-6.
16. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Met Disp. 2003;31:510-8.
17. Gabrielsson J, Jusko WJ, Alari L. Modeling of dose-response-time data: Four examples of generating kinetic functions from response profiles. Biopharm Drug Disp. 2000;21:41-52.